Research programme: CD38 antibody therapeutics - Amorfix Life Sciences

Drug Profile

Research programme: CD38 antibody therapeutics - Amorfix Life Sciences

Latest Information Update: 18 Dec 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amorfix Life Sciences
  • Developer ProMIS Neurosciences; QED Bioscience
  • Class Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Multiple myeloma

Most Recent Events

  • 18 Dec 2014 Suspended for Multiple myeloma in Canada (Parenteral)
  • 18 Jul 2012 Research programme is available for licensing as of 30 Apr 2012.
  • 24 Jun 2010 Early research in Multiple myeloma in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top